Atherosclerosis Global Clinical Trials Review, H1, 2017 - Product Image

Atherosclerosis Global Clinical Trials Review, H1, 2017

  • ID: 4307948
  • Clinical Trials
  • Region: Global
  • 480 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca Plc
  • Eli Lilly and Company
  • Esperion Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • MORE
Atherosclerosis Global Clinical Trials Review, H1, 2017

Summary

The author's clinical trial report, “Atherosclerosis Global Clinical Trials Review, H1, 2017" provides an overview of Atherosclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Atherosclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The Clinical Trial Reports are generated using the proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca Plc
  • Eli Lilly and Company
  • Esperion Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • MORE
Table of Contents
Table of Contents
List of Tables
List of Figures
Report Guidance
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Atherosclerosis to Cardiovascular Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Atherosclerosis to Cardiovascular Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Atherosclerosis Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Atherosclerosis
Mar 20, 2017: Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid
Mar 18, 2017: No Benefit of Synthetic HDL-C on Arterial Plaque
Mar 17, 2017: FOURIER Trial Reveals Significant Reduction in Cardiovascular Risk
Mar 07, 2017: Regeneron and Sanofi to Present New Phase 3 Praluent (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions
Feb 02, 2017: Amgen Announces Repatha (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study
Clinical Trial Profile Snapshots
Appendix 4
Abbreviations 4
Definitions 4
Research Methodology 4
Secondary Research 4
About the Publisher 4
Contact Us 4
Source 4

List of Tables
Atherosclerosis Therapeutics, Global, Clinical Trials by Region, 2017*
Atherosclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Atherosclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Atherosclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*
Atherosclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
Atherosclerosis Therapeutics Clinical Trials, North America, Top Countries, 2017*
Atherosclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017*
Atherosclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017*
Proportion of Atherosclerosis to Cardiovascular Clinical Trials, G7 Countries (%), 2017*
Atherosclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Atherosclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Atherosclerosis to Cardiovascular Clinical Trials, E7 Countries (%), 2017*
Atherosclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Atherosclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Atherosclerosis Therapeutics, Global, Clinical Trials by Phase, 2017*
Atherosclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
Atherosclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Atherosclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Atherosclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Atherosclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
Atherosclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Atherosclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Atherosclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*

List of Figures
Atherosclerosis Therapeutics, Global, Clinical Trials by Region (%), 2017*
Atherosclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Atherosclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Atherosclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*
Atherosclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
Atherosclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
Atherosclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017*
Atherosclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017*
Proportion of Atherosclerosis to Cardiovascular Clinical Trials, G7 Countries (%), 2017*
Atherosclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Atherosclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Atherosclerosis to Cardiovascular Clinical Trials, E7 Countries (%), 2017*
Atherosclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Atherosclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Atherosclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2017*
Atherosclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
Atherosclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Atherosclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Atherosclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Atherosclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
Atherosclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Atherosclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Atherosclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
Methodology
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • GlaxoSmithKline Plc
  • Merck & Co Inc
  • Pfizer Inc
  • AstraZeneca Plc
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • Novartis AG
  • Esperion Therapeutics Inc
  • Abbott Laboratories
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll